Impact of PCV7 on invasive pneumococcal disease among children younger than 5 years: a population-based study.
暂无分享,去创建一个
[1] A. Schuchat,et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The New England journal of medicine.
[2] A. Schuchat,et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. , 2001, JAMA.
[3] S. Dowell,et al. Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis , 2000, Pediatrics.
[4] G. Overturf. Technical Report: Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate and Polysaccharide Vaccines and Antibiotic Prophylaxis , 2000, Pediatrics.
[5] Mark A. Miller,et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. , 2000, JAMA.